References
  1. Brody H. Human papillomavirus. Nature. 2012;488(7413):S1. doi:10.1038/488S1a
  2. Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3-12. doi: 10.1016/j.mrrev.2016.07.002
  3. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2-13. doi: 10.1016/j.bpobgyn.2017.08.015
  4. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14-26. doi:10.1016/j.bpobgyn.2017.08.006
  5. Della Fera AN, Warburton A, Coursey TL, Khurana S, McBride AA. Persistent Human Papillomavirus Infection. Viruses. 2021;13(2):321. doi:10.3390/v13020321
  6. Taylor MM, Wi T, Gerbase A, Thwin SS, Gottlieb S, Babovic MT, et al. Assessment of country implementation of the WHO global health sector strategy on sexually transmitted infections (2016-2021). PLoS One. 2022;17(5):e0263550. doi: 10.1371/journal.pone.0263550
  7. Nguyen HP, Ramírez-Fort MK, Rady PL. The biology of human papillomaviruses. Curr Probl Dermatol. 2014;45:19-32. doi: 10.1159/000355959
  8. Araldi RP, Sant’Ana TA, Módolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, Cerutti JM, de Souza EB. The human papillomavirus (HPV)-related cancer biology: An overview. Biomed Pharmacother. 2018;106:1537-1556. doi:10.1016/j.biopha.2018.06.149.
  9. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25 Suppl 1(Suppl Suppl 1):2-23. doi: 10.1002/rmv.1822.
  10. Cerqueira C, Schiller JT. Papillomavirus assembly: An overview and perspectives. Virus Res. 2017;231:103-107. doi: 10.1016/j.virusres.2016.11.010
  11. McBride AA. Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol. 2022;20(2):95-108. doi: 10.1038/s41579-021-00617-5
  12. Wakabayashi R, Nakahama Y, Nguyen V, Espinoza JL. The Host-Microbe Interplay in Human Papillomavirus-Induced Carcinogenesis. Microorganisms. 2019;7(7):199. doi: 10.3390/microorganisms7070199
  13. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of câncer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-670. doi: 10.1002/ijc.30716
  14. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8
  15. Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80(5):384-92. doi: 10.1016/j.aogh.2014.09.013
  16. Manini I, Montomoli E. Epidemiology and prevention of Human Papillomavirus. Ann Ig. 2018;30(4 Supple 1):28-32. doi: 10.7416/ai.2018.2231
  17. Bogale AL, Belay NB, Medhin G, Ali JH. Molecular epidemiology of human papillomavirus among HIV infected women in developing countries: systematic review and meta-analysis. Virol J. 2020;17(1):179. doi: 10.1186/s12985-020-01448-1
  18. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1-17. doi:10.1128/CMR.16.1.1-17.2003
  19. Florin L, Sapp M, Spoden GA. Host-cell factors involved in papillomavirus entry. Med Microbiol Immunol. 2012;201(4):437-48. doi: 10.1007/s00430-012-0270-1
  20. Day PM, Schelhaas M. Concepts of papillomavirus entry into host cells. Curr Opin Virol. 2014;4:24-31. doi: 10.1016/j.coviro.2013.11.002
  21. Vashisht S, Mishra H, Mishra PK, Ekielski A, Talegaonkar S. Structure, Genome, Infection Cycle and Clinical Manifestations Associated with Human Papillomavirus. Curr Pharm Biotechnol. 2019;20(15):1260-1280. doi: 10.2174/1389201020666190802115722
  22. Stanley M. Host defence and persistent human papillomavirus infection. Curr Opin Virol. 2021;51:106-110. doi: 10.1016/j.coviro.2021.09.010
  23. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004;4(1):46-54. doi: 10.1038/nri1260
  24. Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18(4):240-254. doi: 10.1038/nrc.2018.13
  25. Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020;471:88-102. doi: 10.1016/j.canlet.2019.11.039
  26. Rosalik K, Tarney C, Han J. Human Papilloma Virus Vaccination. Viruses. 2021;13(6):1091. doi: 10.3390/v13061091
  27. Petrie K, Wells A, Eckert LO. Human Papillomavirus Vaccine: The Cancer Prevention Moonshot. Obstet Gynecol Clin North Am. 2023;50(2):339-348. doi: 10.1016/j.ogc.2023.02.006
  28. Quinlan JD. Human Papillomavirus: Screening, Testing, and Prevention. Am Fam Physician. 2021;104(2):152-159.
  29. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, Jin T. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2021;8:552028. doi: 10.3389/fpubh.2020.552028
  30. Chelimo C, Wouldes TA, Cameron LD, Elwood JM. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect. 2013;66(3):207-17. doi: 10.1016/j.jinf.2012.10.024
  31. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020;8(3):391. doi: 10.3390/vaccines8030391
  32. Garbuglia AR, Lapa D, Sias C, Capobianchi MR, Del Porto P. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front Immunol. 2020;11:188. doi: 10.3389/fimmu.2020.00188
  33. Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021;9(12):1413. doi: 10.3390/vaccines9121413
  34. Suresh A, Suresh P, Biswas R, Rajanbabu A, Sreedhar S, Biswas L. Prevalence of high-risk HPV and its genotypes-Implications in the choice of prophylactic HPV vaccine. J Med Virol. 2021;93(8):5188-5192. doi: 10.1002/jmv.27015
  35. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front Immunol. 2022;12:805695. doi: 10.3389/fimmu.2021.805695
  36. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055
  37. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99. doi: 10.1086/657321
  38. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453-9. doi: 10.1016/S1473-3099(07)70158-5
  39. Bhattacharjee R, Das SS, Biswal SS, Nath A, Das D, Basu A, et al. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol. 2022;174:103675. doi: 10.1016/j.critrevonc.2022.103675
  40. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30 Suppl 5:F55-70. doi: 10.1016/j.vaccine.2012.06.083
  41. Oyervides-Muñoz MA, Pérez-Maya AA, Rodríguez-Gutiérrez HF, Gómez-Macias GS, Fajardo-Ramírez OR, Treviño V, et al. Understanding the HPV integration and its progression to cervical cancer. Infect Genet Evol. 2018;61:134-144. doi: 10.1016/j.meegid.2018.03.003
  42. McBride AA, Warburton A, Khurana S. Multiple Roles of Brd4 in the Infectious Cycle of Human Papillomaviruses. Front Mol Biosci. 2021;8:725794. doi: 10.3389/fmolb.2021.725794
  43. Aksoy P, Gottschalk EY, Meneses PI. HPV entry into cells. Mutat Res Rev Mutat Res. 2017;772:13-22. doi:
  44. Doorbar J. Host control of human papillomavirus infection and disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:27-41. doi: 10.1016/j.bpobgyn.2017.08.001
  45. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3 Suppl 2):S4-7. doi: 10.1016/j.ygyno.2008.07.045
  46. Mirghani H, Sturgis EM, Aupérin A, Monsonego J, Blanchard P. Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. Oral Oncol. 2017;67:138-145. doi: 10.1016/j.oraloncology.2017.02.024
  47. Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathog Dis. 2019;77(5):ftz048. doi: 10.1093/femspd/ftz048
  48. Vashisht S, Mishra H, Mishra PK, Ekielski A, Talegaonkar S. Structure, Genome, Infection Cycle and Clinical Manifestations Associated with Human Papillomavirus. Curr Pharm Biotechnol. 2019;20(15):1260-1280. doi: 10.2174/1389201020666190802115722
  49. Li S, Ye M, Chen Y, Gong Q, Mei B. Genetic variation of E6 and E7 genes of human papillomavirus 52 from Central China. J Med Virol. 2021;93(6):3849-3856. doi: 10.1002/jmv.26690
  50. Duvlis S, Dabeski D, Hiljadnikova-Bajro M, Osmani D, Memeti S. HPV E6/E7mRNA association with interleukin 10 (rs1800872) polymorphism in a group of Macedonian women. J Med Virol. 2022;94(9):4485-4489. doi: 10.1002/jmv.27858
  51. Ye M, Li S, Luo P, Tang X, Gong Q, Mei B. Genetic variation of E6, E7, and L1 genes of human papillomavirus 51 from central China. J Med Virol. 2022;94(6):2811-2823. doi: 10.1002/jmv.27603
  52. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144(3):449-68. doi: 10.1017/S0950268815002198. Epub 2015 Oct 2. Erratum in: Epidemiol Infect. 2016 Aug;144(11):2472.
  53. Dai Z, Si M, Su X, Wang W, Zhang X, Gu X, et al. Willingness to human papillomavirus (HPV) vaccination and influencing factors among male and female university students in China. J Med Virol. 2022 Jun;94(6):2776-2786. doi: 10.1002/jmv.27478
  54. Huang R, Gan R, Zhang D, Xiao J. The comparative safety of human papillomavirus vaccines: A Bayesian network meta-analysis. J Med Virol. 2022;94(2):729-736. doi: 10.1002/jmv.27304
  55. Araldi RP, Assaf SMR, Carvalho RF, Carvalho MACR, Souza JM, Magnelli RF, et al. Papillomaviruses: a systematic review. Genet Mol Biol. 2017;40(1):1-21. doi: 10.1590/1678-4685-GMB-2016-0128
  56. Magalhães GM, Vieira ÉC, Garcia LC, De Carvalho-Leite MLR, Guedes ACM, Araújo MG. Update on human papilloma virus - part I: epidemiology, pathogenesis, and clinical spectrum. An Bras Dermatol. 2021;96(1):1-16. doi: 10.1016/j.abd.2020.11.003
  57. Malik S, Sah R, Muhammad K, Waheed Y. Tracking HPV Infection, Associated Cancer Development, and Recent Treatment Efforts-A Comprehensive Review. Vaccines (Basel). 2023;11(1):102. doi: 10.3390/vaccines11010102
  58. Mitra T, Elangovan S. Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA. Mol Cell Biochem. 2021;476(12):4363-4385. doi: 10.1007/s11010-021-04249-4
  59. Shanmugasundaram S, You J. Targeting Persistent Human Papillomavirus Infection. Viruses. 2017;9(8):229. doi: 10.3390/v9080229
  60. Gupta S, Kumar P, Das BC. HPV: Molecular pathways and targets. Curr Probl Cancer. 2018;42(2):161-174. doi: 10.1016/j.currproblcancer.2018.03.003
  61. Gupta AK, Kumar M. HPVomics: An integrated resource for the human papillomavirus epitome and therapeutics. Genomics. 2020;112(6):4853-4862. doi: 10.1016/j.ygeno.2020.08.025
  62. Zhen S, Qiang R, Lu J, Tuo X, Yang X, Li X. CRISPR/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer. J Med Virol. 2023;95(1):e28144. doi: 10.1002/jmv.28144
  63. Dong Z, Hu R, Du Y, Tan L, Li L, Du J, et al. Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers. Front Immunol. 2021;11:586796. doi: 10.3389/fimmu.2020.586796
  64. Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discov. 2021;11(8):1896-1912. doi: 10.1158/2159-8290.CD-20-1760
  65. Guidry JT, Scott RS. The interaction between human papillomavirus and other viruses. Virus Res. 2017;231:139-147. doi: 10.1016/j.virusres.2016.11.002
  66. Vazifehdoost M, Eskandari F, Sohrabi A. Trends in cocirculation of oncogenic HPV genotypes in single and multiple infections among the unvaccinated community. J Med Virol. 2022;94(7):3376-3385. doi: 10.1002/jmv.27706
  67. Rositch AF, Gravitt PE, Tobian AA, Newell K, Quinn TC, Serwadda D, et al. Frequent detection of HPV before and after initiation of antiretroviral therapy among HIV/HSV-2 co-infected women in Uganda. PLoS One. 2013;8(1):e55383. doi: 10.1371/journal.pone.0055383
  68. Massad L, Keller M, Xie X, Minkoff H, Palefsky J, DʼSouza G, et al. Multitype Infections With Human Papillomavirus: Impact of Human Immunodeficiency Virus Coinfection. Sex Transm Dis. 2016a;43(10):637-41. doi: 10.1097/OLQ.0000000000000501
  69. Massad LS, Xie X, Burk RD, D’Souza G, Darragh TM, Minkoff H, et al. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Am J Obstet Gynecol. 2016b;214(3):354.e1-6. doi: 10.1016/j.ajog.2015.09.086
  70. Bacik LC, Chung C. Human papillomavirus-associated cutaneous disease burden in human immunodeficiency virus (HIV)-positive patients: the role of human papillomavirus vaccination and a review of the literature. Int J Dermatol. 2018;57(6):627-634. doi: 10.1111/ijd.13819
  71. Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, et al. Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey. Clin Infect Dis. 2019;69(6):1019-1026. doi: 10.1093/cid/ciy1012
  72. Pérez-González A, Cachay E, Ocampo A, Poveda E. Update on the Epidemiological Features and Clinical Implications of Human Papillomavirus Infection (HPV) and Human Immunodeficiency Virus (HIV) Coinfection. Microorganisms. 2022;10(5):1047. doi: 10.3390/microorganisms10051047
  73. Mulherkar TH, Gómez DJ, Sandel G, Jain P. Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses. Viruses. 2022;14(9):2037. doi: 10.3390/v14092037.
  74. Amirian ES, Adler-Storthz K, Scheurer ME. Associations between human herpesvirus-6, human papillomavirus and cervical cancer. Cancer Lett. 2013;336(1):18-23. doi: 10.1016/j.canlet.2013.04.023
  75. Moharreri M, Sohrabi A. Characteristics of HSV-2, M. genitalium and C. trachomatis in HPV Genotypes Associated with Cervical Intraepithelial Neoplasia and Genital Infections. Infect Disord Drug Targets. 2021;21(1):112-118. doi: 10.2174/1871526520666191231142317
  76. Soares CC, Georg I, Lampe E, Lewis L, Morgado MG, Nicol AF, et al. HIV-1, HBV, HCV, HTLV, HPV-16/18, and Treponema pallidum infections in a sample of Brazilian men who have sex with men. PLoS One. 2014;9(8):e102676. doi: 10.1371/journal.pone.0102676
  77. Shi Y, Peng SL, Yang LF, Chen X, Tao YG, Cao Y. Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis. Chin J Cancer. 2016;35:16. doi: 10.1186/s40880-016-0079-1
  78. Vazquez-Guillen JM, Palacios-Saucedo GC, Rivera-Morales LG, Alonzo-Morado MV, Burciaga-Bernal SB, Montufar-Martinez M, et al. Infection and coinfection by human papillomavirus, Epstein-Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: a retrospective study. PeerJ. 2018;6:e5834. doi: 10.7717/peerj.5834
  79. de Lima MAP, Teodoro IPP, da Silva CGL, Lima MVA. Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Oral and Anogenital Carcinogenesis: Potential Tumorigenic Pathways. Crit Rev Oncog. 2019;24(4):403-413. doi: 10.1615/CritRevOncog.2020033071
  80. Blanco R, Carrillo-Beltrán D, Osorio JC, Calaf GM, Aguayo F. Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Cervical Cancer: Epidemiology, Mechanisms and Perspectives. Pathogens. 2020;9(9):685. doi: 10.3390/pathogens9090685
  81. Harabajsa S, Šefčić H, Klasić M, Milavić M, Židovec Lepej S, Grgić I, et al. Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma. Croat Med J. 2023;64(2):84-92. doi: 10.3325/cmj.2023.64.84
  82. Zhu H, Shen Z, Luo H, Zhang W, Zhu X. Chlamydia Trachomatis Infection-Associated Risk of Cervical Cancer: A Meta-Analysis. Medicine (Baltimore). 2016;95(13):e3077. doi: 10.1097/MD.0000000000003077
  83. Kumari S, Bhor VM. A literature review on correlation between HPV coinfection with C. trachomatis and cervical neoplasia - coinfection mediated cellular transformation. Microb Pathog. 2022;168:105587. doi: 10.1016/j.micpath.2022.105587
  84. Dong B, Huang Y, Cai H, Chen Y, Li Y, Zou H, et al. Prevotella as the hub of the cervicovaginal microbiota affects the occurrence of persistent human papillomavirus infection and cervical lesions in women of childbearing age via host NF-κB/C-myc. J Med Virol. 2022;94(11):5519-5534. doi: 10.1002/jmv.28001
  85. Santella B, Schettino MT, Franci G, De Franciscis P, Colacurci N, Schiattarella A, Galdiero M. Microbiota and HPV: The role of viral infection on vaginal microbiota. J Med Virol. 2022;94(9):4478-4484. doi: 10.1002/jmv.27837
  86. Rosário A, Sousa A, Varandas T, Marinho-Dias J, Medeiros R, Martins G, et al. Impact of cervicovaginal microbiome on the risk of cervical abnormalities development. J Med Virol. 2023;95(5):e28762. doi: 10.1002/jmv.28762
  87. Taku O, Brink A, Meiring TL, Phohlo K, Businge CB, Mbulawa ZZA, Williamson AL. Detection of sexually transmitted pathogens and co-infection with human papillomavirus in women residing in rural Eastern Cape, South Africa. PeerJ. 2021;9:e10793. doi: 10.7717/peerj.10793
  88. Hammer A, Gravitt PE, Adcock R, Patterson N, Cuzick J, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Burden of Mycoplasma genitalium and Bacterial Coinfections in a Population-Based Sample in New Mexico. Sex Transm Dis. 2021;48(12):e186-e189. doi: 10.1097/OLQ.0000000000001472
  89. Verteramo R, Pierangeli A, Mancini E, Calzolari E, Bucci M, Osborn J, et al. Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infect Dis. 2009;9:16. doi: 10.1186/1471-2334-9-16
  90. Gholizadeh O, Yekanipour Z, Kivi S, Farahbod F, Aqayinejad M, Tasoujizade Y, Yasamineh S, et al. Review of the evidence of the effects of human papillomavirus infection and Gardnerella vaginalis, and their co-infection on infertility. Microb Pathog. 2023;175:105980. doi: 10.1016/j.micpath.2023.105980
  91. da Silva BEB, Santos VS, Santos IER, Araújo ED, Alves MV, Silva LADS, et al. Prevalence and genotype distribution of human papillomavirus in women living with HIV/AIDS in an area of Northeast Brazil. J Med Virol. 2020 Apr 24. doi: 10.1002/jmv.25935
  92. Paula Almeida Cunha A, Kassandra Pereira Belfort I, Pedro Belfort Mendes F, Rodrigues Bastos Dos Santos G, Henrique de Lima Costa L, de Matos Monteiro P, et al. Human papillomavirus and Its Association with Other Sexually Transmitted Coinfection among Sexually Active Women from the Northeast of Brazil. Interdiscip Perspect Infect Dis. 2020;2020:8838317. doi: 10.1155/2020/8838317
  93. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781-9. doi: 10.1016/S1470-2045(10)70017-6
  94. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017
  95. Spence T, Bruce J, Yip KW, Liu FF. HPV Associated Head and Neck Cancer. Cancers (Basel). 2016;8(8):75. doi: 10.3390/cancers8080075.
  96. Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123(12):2219-2229. doi: 10.1002/cncr.30588
  97. Tanaka TI, Alawi F. Human Papillomavirus and Oropharyngeal Cancer. Dent Clin North Am. 2018;62(1):111-120. doi: 10.1016/j.cden.2017.08.008
  98. Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020;122(3):306-314. doi: 10.1038/s41416-019-0602-7
  99. Tumban E. A Current Update on Human Papillomavirus-Associated Head and Neck Cancers. Viruses. 2019;11(10):922. doi: 10.3390/v11100922
  100. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. doi: 10.1038/s41572-020-00224-3. Erratum in: Nat Rev Dis Primers. 2023 Jan 19;9(1):4.
  101. Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398(10318):2289-2299. doi: 10.1016/S0140-6736(21)01550-6
  102. Nogues JC, Fassas S, Mulcahy C, Zapanta PE. Human Papillomavirus-Associated Head and Neck Cancer. J Am Board Fam Med. 2021;34(4):832-837. doi: 10.3122/jabfm.2021.04.200588
  103. Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306-327. doi: 10.1038/s41571-022-00603-7
  104. Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK, et al. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Mol Cancer. 2022 ;21(1):31. doi: 10.1186/s12943-022-01503-1
  105. Trivedi S, Sun L, Aggarwal C. Immunotherapy for Head and Neck Cancer. Hematol Oncol Clin North Am. 2021;35(5):1021-1037. doi: 10.1016/j.hoc.2021.05.010
  106. Palefsky JM. Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era. Curr Opin HIV AIDS. 2017;12(1):26-30. doi: 10.1097/COH.0000000000000336
  107. Wang CJ, Sparano J, Palefsky JM. Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. Surg Oncol Clin N Am. 2017;26(1):17-31. doi: 10.1016/j.soc.2016.07.010
  108. Otter S, Whitaker S, Chatterjee J, Stewart A. The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers. Clin Oncol (R Coll Radiol). 2019;31(2):81-90. doi: 10.1016/j.clon.2018.10.004
  109. Valvo F, Ciurlia E, Avuzzi B, Doci R, Ducreux M, Roelofsen F, et al. Cancer of the anal region. Crit Rev Oncol Hematol. 2019;135:115-127. doi: 10.1016/j.critrevonc.2018.12.007
  110. Wang CJ, Palefsky JM. HPV-Associated Anal Cancer in the HIV/AIDS Patient. Cancer Treat Res. 2019;177:183-209. doi: 10.1007/978-3-030-03502-0_7
  111. Albuquerque A, Nathan M, Cappello C, Dinis-Ribeiro M. Anal cancer and precancerous lesions: a call for improvement. Lancet Gastroenterol Hepatol. 2021;6(4):327-334. doi: 10.1016/S2468-1253(20)30304-6
  112. Vegunta S, Shah AA, Whited MH, Long ME. Screening Women for Anal Cancers: Guidance for Health Care Professionals. Am J Gastroenterol. 2021;116(3):509-516. doi: 10.14309/ajg.0000000000001186
  113. Eng C, Ciombor KK, Cho M, Dorth JA, Rajdev LN, Horowitz DP, et al. Anal Cancer: Emerging Standards in a Rare Disease. J Clin Oncol. 2022;40(24):2774-2788. doi: 10.1200/JCO.21.02566